Please select the eligibility criteria that correspond to the clinical trial below.
Title: Magnesium Oxide Monohydrate for Nocturnal Leg Cramps (MgNLC); a Prospective, Randomized, Double Blind, Placebo Controlled Clinical Trial.
Brief Summary: Nocturnal leg cramps (NLC) are painful, involuntary contractions of muscles occurring at rest, mostly at night. A Cochrane review on leg cramps in pregnancy showed some potential benefits in trials of magnesium. This is a single center, prospective, randomized, double blind, placebo controlled clinical trial that aims to investigate the effect of treatment with Magnox 520® (un-organic granular magnesium complex, composed of Magnesium Oxide \& Magnesium Oxide Monohydrate 865mg, Provides 520 mg of free elemental Mg++) on frequency and severity of NLC, quality of sleep and quality of life. Hypothesis: Magnox 520® may reduce the number and severity of NLC; an improvement in the quality of life and quality of sleep may ensue.


Options:
A: Inclusion Criteria:

* Biopsy-proven or clinically evident cirrhosis
* Able to perform exercise

Exclusion Criteria:

* Overt hepatic encephalopathy grades 3 or 4
* Cardiovascular complications (pulmonary hypertension, heart failure)
* Diabetes mellitus and microangiopathic complications, or under treatment with insulin
* Renal failure
* Portal hypertension with high risk for variceal bleeding
* Hepatocellular carcinoma
B: Inclusion Criteria:

* For patients to be included in our study, they had to experience regular episodes of NLC and are in good mental health.
* The participants had to agree to the study protocol and complete the program.
* After eligibility was verified, written informed consent was obtained.

Exclusion Criteria:

* Older adults taking quinine or sleep medication and those with orthopedic problems or with severe medical problems and co morbidity, which can cause muscular spasms and/or cramps.
C: Inclusion Criteria:

Signed informed consent before any procedure or assessment is done. Age over 21 years old. Over 4 episodes of documented NLC during 2 weeks of eligibility screening (for the treatment phase).

Insured by Clalit Health Services (CHS). Hebrew speaking

Exclusion Criteria:

Pregnancy Currently taking Quinidine or Magnesium additive Renal failure - serum creatinine more than 2 mg/DL or estimated glomerular filtration rate (eGFR) less than 60 ml/min (the worst, ascertained by the participant electronic records in the last 6 months). If the result is near these limits (i.e. serum creatinin 1.5-2) a second analysis will be done near the study enrollment.

Major neurological disease- ALS, MS, Paraplegia or Quadriplegia.
D: Inclusion Criteria:

* Diagnosis of chronic kidney disease and receiving dialysis treatment
* Previous experience of at least 2 or more muscle cramps per month in at least 3 of the last 6 months
* Men or women aged 18 years and older
* Capacity to provide informed consent

Exclusion Criteria:

* Patients less than 18 years of age
* Women who are pregnant and the human fetus
* Serious, uncontrolled disease (including serious psychological disorders) likely to interfere with the study and/or likely to cause death within the study duration
* Participation in another clinical during the last 12 weeks
* Known allergic reactions against any component of the study drug or its comparator(s)
* Known contraindication to any component of the study drug or its comparator(s)
* Concurrent diseases which exclude the administration of therapy as outlined by the study protocol
* Subjects who, in the opinion of the investigator, are not likely to complete the study for whatever reason.

Answer: C